公开(公告)号：US20220372125A1

公开(公告)日：2022-11-24

申请号：US17766131

申请日：2020-10-02

Applicant: Aslan Pharmaceuticals Pte. Ltd. ,  Agency for Science, Technology and Research

Inventor： Xin Yu Koh ,  David Philip Lane

IPC: C07K16/22 ,  A61K47/68 ,  A61P35/00 ,  A61K51/10

Abstract: The present disclosure relates to an antigen specific binding domain which binds to RON (Macrophage Stimulating Protein Receptor or Recepteur d'Origine Nantais). The disclosure also extends to chimeric antigen receptors (and a cell expressing the same), antibody molecules (including full length antibodies and fragments thereof, as well as antibody conjugates) containing the antigen binding domains disclosed herein. Also disclosed herein are pharmaceutical compositions comprising the cells, antibody molecules as disclosed herein. The present disclosure also refers to the use of the antigen binding domains, the chimeric antigen receptors, the antibody molecules and the pharmaceutical compositions disclosed herein in therapy, more particularly in treating cancer. Also disclosed herein are radiolabelled antibody conjugates comprising the antigen binding domains as disclosed, and their use in methods of treatment or diagnosis.

公开(公告)号：US09994644B2

公开(公告)日：2018-06-12

申请号：US14888354

申请日：2014-03-28

Applicant: Agency for Science, Technology and Research

Inventor： Shuxian Julin Wong ,  David Philip Lane

IPC: C07K16/32 ,  C07K16/28 ,  G01N33/574 ,  A61K47/48

CPC classification number: C07K16/32 ,  A61K47/6803 ,  A61K47/6851 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/94 ,  G01N33/57492 ,  G01N2333/71

Abstract: Antibodies specifically binding an epitope comprised in the α-chain of c-Met, modifications, compositions and uses thereof are disclosed herein.

公开(公告)号：US20160046672A1

公开(公告)日：2016-02-18

申请号：US14778761

申请日：2014-02-28

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Christopher John Brown ,  David Philip Lane ,  Soo Tng Quah ,  Dilraj Lama ,  Chandra Shekhar Verma

IPC: C07K7/08

CPC classification number: C07K7/08 ,  A61K38/00 ,  C07K14/4705

Abstract: The present invention relates to cross-linked peptides that are associated with human eIF4G and bind to eIF4E, uses thereof and pharmaceutical compositions comprising the peptides.

Abstract translation: 本发明涉及与人eIF4G相关并结合eIF4E的交联肽，其用途和包含该肽的药物组合物。

公开(公告)号：US20150276755A1

公开(公告)日：2015-10-01

申请号：US14438469

申请日：2013-10-25

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Farid Ghadessy ,  Chandra Shekhar Verma ,  David Philip Lane ,  Jia Wei Siau ,  Thomas Leonard Joseph ,  Adelene Yen Ling Sim

IPC: G01N33/68 ,  C12Q1/68

CPC classification number: G01N33/6845 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N2333/4748 ,  G01N2333/9015 ,  G01N2500/02

Abstract: The present disclosure provides a method of determining resistance of a biological molecule to inhibition of its interaction with a target molecule by an inhibitor of the biological molecule, the method comprising the steps of: a) co-compartmentalizing a gene encoding the biological molecule with the target molecule, or a gene encoding the biological molecule with a gene encoding the target molecule into an aqueous droplet disposed within a water-in-oil emulsion, and b) assaying for a complex comprising the biological molecule and the target molecule upon expression of the gene encoding the biological molecule and the gene encoding the target molecule, wherein detection of the complex in the presence of the inhibitor indicates that the biological molecule is resistant to inhibition of its interaction with the target molecule by the inhibitor. Also provided are mutated HDM2 ubiquitin ligase polypeptides exhibiting resistance to Nutlin inhibition of p53 binding.

Abstract translation: 本公开提供了一种确定生物分子对生物分子的抑制剂与靶分子的相互作用的抗性的方法，所述方法包括以下步骤：a）将编码生物分子的基因与 目标分子或编码具有编码靶分子的基因的生物分子的基因转化成布置在油包水乳液中的水滴，以及b）在表达后，测定包含生物分子和靶分子的复合物 编码生物分子的基因和编码靶分子的基因，其中在抑制剂存在下检测复合物表明生物分子对抑制剂与靶分子的相互作用的抑制具有抗性。 还提供了显示出对Nutlin抑制p53结合的抗性的突变的HDM2泛素连接酶多肽。